Hyper-oxygenation, oxidative stress, and kidney injury following cardiac surgery
心脏手术后的高氧合、氧化应激和肾损伤
基本信息
- 批准号:9253963
- 负责人:
- 金额:$ 10.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-01 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Each year 500,000 patients undergo cardiac surgery in the United States, and acute kidney injury (AKI) complicates recovery in 25% of patients. AKI is associated with subsequent postoperative arrhythmias, wound infections, and sepsis, and independently predicts a 5-fold increase in death at 30 days. The principal investigator has demonstrated that intraoperative concentrations of F2-isoprostanes, products of reactive oxygen species (ROS)-induced arachidonic acid peroxidation, independently predict AKI following cardiac surgery, suggesting that treatments that target excess ROS production during surgery may reduce AKI. Hyper-oxygenation - the administration of oxygen in excess of that required to saturate hemoglobin - is prevalent during cardiac surgery despite frequent renal ischemia. In vitro and following experimental ischemia hyper-oxygenation increases ROS production. Our preliminary studies indicate that hyper-oxygenation increases ROS production in blood ex vivo and maintaining physiologic oxygenation during cardiac surgery by restricting oxygen administration to that required to saturate hemoglobin is feasible and safe and associated with decreased F2-isoprostanes and AKI compared to hyper-oxygenation. These findings are consistent with recent clinical studies in cardiac arrest patients demonstrating that hyper-oxygenation after resuscitation increases cognitive dysfunction, coma, and death. This project challenges the prevailing culture that the administration of excess oxygen during surgery is beneficial. The research team comprised of experts in cardiac surgery clinical trials, oxidative stress, and AKI, will test the hypothesis that physiologic oxygenation during cardiac surgery decreases postoperative kidney injury (Aim 1), ROS production, and oxidative stress (Aim 2) compared to hyper-oxygenation. The team will complete a phase II clinical trial in which they will recruit and randomize 200 cardiac surgery subjects to receive hyper-oxygenation (fraction of inspired oxygen (FIO2) = 0.8-1.0) or physiologic oxygenation (minimum FIO2 required to achieve a Hb O2 saturation of 95-98% and an arterial pO2 between 80-95 mmHg) during surgery and compare kidney function and injury between treatment groups, ROS production using electron paramagnetic resonance, and systemic oxidative stress by measuring F2-isoprostanes and isofurans in plasma. Safety endpoints will be clinical outcomes associated with hypoxia. Secondary endpoints will be other clinical outcomes associated with excess oxygen administration in preliminary and published studies. By comparing oxidative stress measurements to kidney injury the team will also test the hypothesis that oxidative stress is the mechanism by which anesthesia and surgery induce AKI. Results of these studies have the potential to fundamentally alter the intraoperative management of cardiac surgery patients and enhance the understanding of mechanisms of surgery-induced AKI.
描述(由申请人提供):美国每年有 500,000 名患者接受心脏手术,急性肾损伤 (AKI) 使 25% 的患者康复变得复杂。 AKI 与随后的术后心律失常、伤口感染和败血症相关,并独立预测 30 天时死亡率会增加 5 倍。主要研究人员证明,F2-异前列烷(活性氧 (ROS) 诱导的花生四烯酸过氧化的产物)的术中浓度可独立预测心脏手术后的 AKI,这表明针对手术期间过量 ROS 产生的治疗可能会减少 AKI。尽管经常发生肾缺血,但心脏手术期间,过度氧合(施用的氧气超过血红蛋白饱和所需的氧气)仍然很常见。体外和实验后的缺血过度氧合会增加 ROS 的产生。我们的初步研究表明,与过度氧合相比,过度氧合可增加离体血液中 ROS 的产生,并通过将供氧限制在使血红蛋白饱和所需的量来维持心脏手术期间的生理氧合是可行且安全的,并且与减少 F2-异前列烷和 AKI 相关。这些发现与最近对心脏骤停患者的临床研究一致,表明复苏后的过度氧合会增加认知功能障碍、昏迷和死亡。该项目挑战了手术期间使用过量氧气有益的流行文化。该研究小组由心脏手术临床试验、氧化应激和 AKI 方面的专家组成,将测试以下假设:与高氧相比,心脏手术期间的生理氧合可减少术后肾损伤(目标 1)、ROS 产生和氧化应激(目标 2)。 -氧化。该团队将完成一项 II 期临床试验,其中他们将招募并随机分配 200 名心脏手术受试者,接受高氧合(吸入氧分数 (FIO2) = 0.8-1.0)或生理氧合(达到 Hb O2 所需的最低 FIO2)手术期间饱和度为 95-98%,动脉氧分压在 80-95 mmHg 之间),并比较治疗组之间的肾功能和损伤,使用 ROS 产生电子顺磁共振,通过测量血浆中的 F2-异前列腺素和异呋喃来评估全身氧化应激。安全终点将是与缺氧相关的临床结果。次要终点将是初步和已发表研究中与过量供氧相关的其他临床结果。通过将氧化应激测量值与肾损伤进行比较,研究小组还将检验氧化应激是麻醉和手术诱发 AKI 机制的假设。这些研究的结果有可能从根本上改变心脏手术患者的术中管理,并增强对手术诱发 AKI 机制的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Frederic Tremaine Billings其他文献
Frederic Tremaine Billings的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Frederic Tremaine Billings', 18)}}的其他基金
Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty
减少围术期氧化应激以预防全膝关节置换术后慢性疼痛
- 批准号:
10793361 - 财政年份:2023
- 资助金额:
$ 10.78万 - 项目类别:
Repurposing Montelukast for Cardiac Surgery-Associated Acute Kidney Injury
重新利用孟鲁司特治疗心脏手术相关的急性肾损伤
- 批准号:
10043764 - 财政年份:2020
- 资助金额:
$ 10.78万 - 项目类别:
Hyper-oxygenation, oxidative stress, and kidney injury following cardiac surgery
心脏手术后的高氧合、氧化应激和肾损伤
- 批准号:
8801217 - 财政年份:2015
- 资助金额:
$ 10.78万 - 项目类别:
Hyper-oxygenation, oxidative stress, and kidney injury following cardiac surgery
心脏手术后的高氧合、氧化应激和肾损伤
- 批准号:
9113044 - 财政年份:2015
- 资助金额:
$ 10.78万 - 项目类别:
Mitochondrial dysfunction, oxidative stress, and surgical acute kidney injury
线粒体功能障碍、氧化应激和手术急性肾损伤
- 批准号:
8520356 - 财政年份:2012
- 资助金额:
$ 10.78万 - 项目类别:
Mitochondrial dysfunction, oxidative stress, and surgical acute kidney injury
线粒体功能障碍、氧化应激和手术急性肾损伤
- 批准号:
8885846 - 财政年份:2012
- 资助金额:
$ 10.78万 - 项目类别:
Mitochondrial dysfunction, oxidative stress, and surgical acute kidney injury
线粒体功能障碍、氧化应激和手术急性肾损伤
- 批准号:
8704361 - 财政年份:2012
- 资助金额:
$ 10.78万 - 项目类别:
相似国自然基金
情志应激通过磷脂酰肌醇过氧化介导的巨噬细胞M2极化增加乳腺癌“易感性”
- 批准号:82004231
- 批准年份:2020
- 资助金额:16.0 万元
- 项目类别:青年科学基金项目
草菇脂肪氧合酶介导PUFA氧化驱动肌原纤维蛋白低盐凝胶的机理
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
HO-1调控ferritin自噬依赖性降解在氧化锌纳米颗粒诱发血管内皮细胞铁死亡和血管内皮损伤中的机制研究
- 批准号:81903358
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
肼合酶模型蛋白理性设计及其在微生物厌氧氨氧化中的应用
- 批准号:21878020
- 批准年份:2018
- 资助金额:66.0 万元
- 项目类别:面上项目
基于光诱导的小米脂质氧化劣变机理研究
- 批准号:31801605
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Leveraging Automated Optimization of Inspired Oxygen and Oxidized Biomarker Lipidomics for Targeted Oxygenation during Mechanical Ventilation: a Pragmatic Clinical Trial
利用吸入氧和氧化生物标志物脂质组学的自动优化在机械通气期间进行靶向氧合:一项实用的临床试验
- 批准号:
10592000 - 财政年份:2023
- 资助金额:
$ 10.78万 - 项目类别:
Validation of OXPHOS gene amplification as a driver of hypoxia and treatment resistance in NSCLC
验证 OXPHOS 基因扩增作为 NSCLC 缺氧和治疗抵抗的驱动因素
- 批准号:
10648605 - 财政年份:2023
- 资助金额:
$ 10.78万 - 项目类别:
Peri-operative factors that drive cell-free hemoglobin-mediated primary graft dysfunction
驱动无细胞血红蛋白介导的原发性移植物功能障碍的围手术期因素
- 批准号:
10431493 - 财政年份:2022
- 资助金额:
$ 10.78万 - 项目类别:
Novel Pathways and Therapeutic Targets for Cisplatin-Associated Acute Kidney Injury
顺铂相关急性肾损伤的新途径和治疗靶点
- 批准号:
10549309 - 财政年份:2022
- 资助金额:
$ 10.78万 - 项目类别: